Literature DB >> 20833683

CYP2C19*2 and CYP2C9*3 alleles are associated with stent thrombosis: a case-control study.

Ankie M Harmsze1, Jochem W van Werkum, Jurriën M Ten Berg, Bastiaan Zwart, Heleen J Bouman, Nicoline J Breet, Arnoud W J van 't Hof, Hendrik J T Ruven, Christian M Hackeng, Olaf H Klungel, Anthonius de Boer, Vera H M Deneer.   

Abstract

AIMS: despite treatment with clopidogrel on top of aspirin, stent thrombosis (ST) still occurs being the most serious complication after percutaneous coronary interventions (PCIs). In this study, we aimed to determine the effect of variations in genes involved in the absorption (ABCB1 C1236T, G2677T/A, C3435T), metabolism (CYP2C19*2 and *3, CYP2C9*2 and *3, CYP3A4*1B and CYP3A5*3), and pharmacodynamics (P2Y1 A1622G) of clopidogrel on the occurrence of ST. METHODS AND
RESULTS: the selected genetic variants were assessed in 176 subjects who developed ST while on dual antiplatelet therapy with aspirin and clopidogrel and in 420 control subjects who did not develop adverse cardiovascular events, including ST, within 1 year after stenting. The timing of the definite ST was acute in 66, subacute in 87, and late in 23 cases. The presence of the CYP2C19*2 and CYP2C9*3 variant alleles was significantly associated with ST (OR(adj): 1.7, 95% CI: 1.0-2.6, P = 0.018 and OR(adj): 2.4, 95% CI: 1.0-5.5, P = 0.043, respectively). The influence of CYP2C19*2 (OR(adj): 2.5, 95% CI: 1.1-5.5, P = 0.026) and CYP2C9*3 (OR(adj): 3.3, 95% CI: 1.1-9.9, P = 0.031) was most strongly associated with subacute ST. No significant associations of the other genetic variations and the occurrence of ST were found.
CONCLUSION: carriage of the loss-of-function alleles CYP2C19*2 and CYP2C9*3 increases the risk on ST after PCI.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20833683     DOI: 10.1093/eurheartj/ehq321

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  40 in total

Review 1.  Personalized vascular medicine: individualizing drug therapy.

Authors:  Emil M Degoma; Giovanni Rivera; Scott M Lilly; M Haris U Usman; Emile R Mohler
Journal:  Vasc Med       Date:  2011-10       Impact factor: 3.239

Review 2.  CYP2C19 polymorphism and clinical outcomes among patients of different races treated with clopidogrel: A systematic review and meta-analysis.

Authors:  Xuan Niu; Ling Mao; Yan Huang; Suraj Baral; Jian-Yong Li; Yuan Gao; Yuan-Peng Xia; Quan-Wei He; Meng-Die Wang; Man Li; Li Zou; Xiao-Ping Miao; Bo Hu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2015-04-16

Review 3.  Genome-wide and candidate gene approaches of clopidogrel efficacy using pharmacodynamic and clinical end points-Rationale and design of the International Clopidogrel Pharmacogenomics Consortium (ICPC).

Authors:  Thomas O Bergmeijer; Jean-Luc Reny; Ruth E Pakyz; Li Gong; Joshua P Lewis; Eun-Young Kim; Daniel Aradi; Israel Fernandez-Cadenas; Richard B Horenstein; Ming Ta Michael Lee; Ryan M Whaley; Joan Montaner; Gian Franco Gensini; John H Cleator; Kiyuk Chang; Lene Holmvang; Willibald Hochholzer; Dan M Roden; Stefan Winter; Russ B Altman; Dimitrios Alexopoulos; Ho-Sook Kim; Jean-Pierre Déry; Meinrad Gawaz; Kevin Bliden; Marco Valgimigli; Rossella Marcucci; Gianluca Campo; Elke Schaeffeler; Nadia P Dridi; Ming-Shien Wen; Jae Gook Shin; Tabassome Simon; Pierre Fontana; Betti Giusti; Tobias Geisler; Michiaki Kubo; Dietmar Trenk; Jolanta M Siller-Matula; Jurriën M Ten Berg; Paul A Gurbel; Jean-Sebastien Hulot; Braxton D Mitchell; Matthias Schwab; Marylyn DeRiggi Ritchie; Teri E Klein; Alan R Shuldiner
Journal:  Am Heart J       Date:  2017-12-17       Impact factor: 4.749

Review 4.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

5.  Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.

Authors:  Yajing Zhai; Hairong He; Xiancang Ma; Jiao Xie; Ti Meng; Yalin Dong; Jun Lu
Journal:  Eur J Clin Pharmacol       Date:  2017-04-05       Impact factor: 2.953

Review 6.  Genetic determinants of response to cardiovascular drugs.

Authors:  Quinn S Wells; Jessica T Delaney; Dan M Roden
Journal:  Curr Opin Cardiol       Date:  2012-05       Impact factor: 2.161

Review 7.  Recent advances in the pharmacogenetics of clopidogrel.

Authors:  Thomas Cuisset; Pierre-Emmanuel Morange; Marie-Christine Alessi
Journal:  Hum Genet       Date:  2011-12-30       Impact factor: 4.132

8.  Feasibility and implementation of CYP2C19 genotyping in patients using antiplatelet therapy.

Authors:  Thomas O Bergmeijer; Gerrit Ja Vos; Daniël Mf Claassens; Paul Wa Janssen; Remko Harms; Richard van der Heide; Folkert W Asselbergs; Jurriën M Ten Berg; Vera Hm Deneer
Journal:  Pharmacogenomics       Date:  2018-04-27       Impact factor: 2.533

Review 9.  Clopidogrel and warfarin pharmacogenetic tests: what is the evidence for use in clinical practice?

Authors:  Mohamed H A Shahin; Julie A Johnson
Journal:  Curr Opin Cardiol       Date:  2013-05       Impact factor: 2.161

10.  Association between CYP2C19 Polymorphisms and Outcomes in Cerebral Endovascular Therapy.

Authors:  M Lin; M Todaro; J Chan; L Churilov; W S Zhu; S Ramdave; P J Mitchell; R J Dowling; P Kwan; B Yan
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-03       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.